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1. Introduction 
In 1978, a simplified technique for peritoneal dialysis (PD) using plastic bags and glucose as 
osmotic agent allowed PD to become accepted as a home-based renal replacement therapy. 
However, PD was marred by complications including peritonitis and loss of function of the 
peritoneal membrane. Both complications may be favored by the bioincompatibility of PD 
solutions. The composition of PD solutions has evolved over the years, building on a better 
understanding of the biocompatibility and of technical advances that enable the commercial 
viability of certain solutions. The main osmotic agent used to obtain ultrafiltration is glucose. 
Conventional glucose-containing PD solutions are lactate-buffered, acidic pH solutions 
presented in single chambered bags. The use of new manufacturing techniques, buffer 
presentation, and new osmotic alternatives to glucose have resulted in more biocompatible 
glucose containing PD solutions that have a lower concentration of glucose degradation 
products (GDP) and a neutral, more physiological pH, as well as in glucose-free solutions. 
2. Composition of PD solutions 
PD solutions are sterile and contain water, electrolytes, a buffer and an osmotic agent (Table 
1). Electrolyte concentrations (Na+, Cl-, Ca++, Mg++) display little variation between different 
PD solutions.  
 
 Water 
 Electrolytes: Na+, Cl-, Ca++, Mg++ 
 Buffer: lactate, lactate / bicarbonate or bicarbonate 
 Osmotic agent glucose, icodextrin or amino acids 
 Glucose degradation products (GDPs) are not added on purpose, but are generated 
during heat sterilization, especially in conventional glucose-containing solutions. 
Table 1. Composition of PD Solutions 
PD solutions contain an osmotic agent that allows a negative balance of fluids 
(ultrafiltration). Glucose is the most widely used osmotic agent. The only alternative osmotic 
agents available are 7.5% icodextrin and a 1.1% amino acid mixture (Frampton, J. E. et al. 
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2003) (Tjiong, H. L. et al. 2005). Neither avoids the use of glucose as only one daily exchange 
of each glucose-free PD solution can be used. There are solutions with three different 
concentrations of glucose in order to individualize ultrafiltration. The highest concentrations 
of glucose obtains more ultrafiltration, but also enhances the adverse effects of glucose and 
in conventional solutions, of the GDPs. The glucose concentration of each of the three types 
of solutions varies with the manufacturer and ranges between 1360 and 4250 mg / dl, 
resulting in an osmolarity of 345 to 511 mOsm / L. There is some confusion in the literature 
regarding the concentration of glucose in the various solutions because in America it is 
expressed as the concentration of dextrose (glucose monohydrate with a molecular weight 
of 198 Da), and in Europe as the concentration of glucose (anhydrous glucose molecular 
weight 180 Da). Thus a dextrose concentration of 1.5%, 2.5% and 4.25% is the same as a 
glucose concentration of 1.36%, 2.27% and 3.86% respectively, but a concentration of glucose 
1.5% corresponds to 1.65% dextrose. 
Lactate is the most common buffer in PD solutions. Recently solutions buffered with lactate 
/ bicarbonate or bicarbonate alone have been marketed, presented in bicameral bags to keep 
separate the bicarbonate from calcium and magnesium until just before the infusion, thereby 
avoiding precipitation (Fig. 1) (Montenegro, J. et al. 2006; Feriani, M. et al. 1998; 
Montenegro, J. et al. 2007; Tranaeus, A.2000; Schmitt, C. P. et al. 2002; Pecoits-Filho, R. et al. 
2003; Otte, K. et al. 2003). Bi- or tricameral bags also allow the separation of glucose and 
buffer until just before the infusion. Thus, glucose is contained in a low pH chamber and the 
buffer in a high pH chamber. The use of acetate as a buffer was abandoned years ago due to 
undesirable effects including vasodilation, decreased myocardial contractility, and 
sclerosing peritonitis. 
 
 
Fig. 1. Bicameral and tricameral PD bags. A and B) Bicameral bags. C) Tricameral bags. Bi- 
and tricameral bags are used to manufacture biocompatible PD solutions. Separating 
glucose form the buffer allows heat sterilization of the bags while minimizing the generation 
of GDPs. 
3. Biocompatibility 
Biocompatibility is the ability of a technique or system to fulfill its function without causing 
a clinically significant adverse response of the host. In PD the concept was initially applied 
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to the influence of PD solutions on the biological responses of peritoneal tissues and cells, 
and the morphology and function of the peritoneum (Holmes, C. J. et al. 2003). In addition 
PD solutions may also have systemic adverse effects (Pecoits-Filho, R. et al. 2003). 
Conventional solutions are bioincompatible mainly due to the high concentration of glucose 
and GDPs. The low pH, high osmolarity and the presence of high concentrations of lactate 
also contribute to bioincompatibility (Table 2). These factors may cause adverse effects on 
celular systems, including dysfunction and death of mesothelial cells and leukocytes. In this 
regard, GDPs are the most lethal factor (Ortiz, A. et al. 2006). 
The consequences of bioincompatibility include worsening of peritoneal defense against 
infection and injury, loss of peritoneal mesothelial cells, epithelial-mesenchymal 
transformation (EMT) of mesothelial cells, fibrosis, diabetiform changes of vessels and 
possibly peritoneal sclerosis (Yanez-Mo, M. et al. 2003; Catalan, M. P. et al. 2001; Williams, J. 
D. et al. 2002). Among systemic consequences we find increased circulating advanced 
glycation products (AGEs), glucose metabolic effects, and poorer preservation of residual 
renal function (Montenegro, J. et al. 2007; Williams, J. D. et al. 2004; Kim, S. G. et al. 2008; 
Zeier, M. et al. 2003). 
 
High concentration of glucose 
Glucose degradation products (GDPs) 
High osmolarity 
Acid pH 
Lactate
Table 2. Elements contributing to the poor biocompatibility of PD solutions 
New solutions have been designed with a neutral pH, without lactate, lack of glucose 
and/or low concentrations of GDPs (Table 3)(McIntyre, C. W.2007; Montenegro, J. et al. 
1993).  
 
  New Solutions New Solutions 
 Conventional Alternative osmotic agents Biocompatible dextrose 
Container Unicameral unicameral  bi or tri-cameral 
Osmotic agent Glucose Icodextrin, amino acids glucose 
GDPs content High low or no low 
pH  5.5 5.8 to 6.5 6.3 to 7.4 
Buffer lactate  lactate  lactate, bicarbonate, 
lactate/bicarbonate 
Table 3. PD Solutions 
Biocompatibility of new solutions has been amply demonstrated in studies in cultured cells 
and animal models and they are expected to improve peritoneal defense and survival of the 
peritoneal membrane function and residual renal function. Clinical experience so far in 
clinical trials, though still incomplete, tends to support these expectations (Table 4). 
PD solutions plastic bags may also contribute to bioincompatibility, although the precise 
contribution has not been established. The conventional material the bags are made of is PVC 
(polyvinyl chloride). PVC is difficult to recycle and contains plasticizers such as phthalic acid. 
Phthalic acid released from the bags can eventually be absorbed from the peritoneum 
(Mettang, T. et al. 2000), although it is unclear whether this represents a health risk. New 
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materials, such as Biofine ®, a polyolefin which needs no plasticizers, Steriflex ® or Clearflex ® 
are thought to be more biocompatible. Conventional bags are single chambered and filled with 
the dialysis solution composition that is infused into the peritoneum (NO CITATION 
DEFINITION). The new glucose solutions are packaged in bi or tricameral bags and the 
contents of the chambers is mixed just before infusion into the peritoneum (Fig 1). This allows 
to sterilize glucose at low pH, thus decreasing the production of GDPs, and to separate the 
calcium and magnesium from bicarbonate to avoid precipitation. 
 
Surrogate markers  
 Increased CA125 biomarker in the peritoneal effluent (Williams, J. D. et 
al. 2004; Fusshoeller, A. et al. 2004; Jones, S. et al. 2001; Haas, S. et al. 
2003; Rippe, B. et al. 2001) 
Lower circulating AGEs (Fusshoeller, A. et al. 2004; Williams, J. D. et al. 
2004) 
Better correction of acidosis (Montenegro, J. et al. 2006; Tranaeus, A.2000; 
Otte, K. et al. 2003; Carrasco, A. M. et al. 2001; Haas, S. et al. 2003) 
Better preserved residual renal function (Montenegro, J. et al. 2007; 
Williams, J. D. et al. 2004; Kim, S. G. et al. 2008) 
No change (Fan, S. L. et al. 2008) 
Clinical Results  
 Mortality decreased (Lee, H. Y. et al. 2005; Lee, H. Y. et al. 2006) 
Decreases peritonitis rate (Montenegro, J. et al. 2007; Ahmad, S. et al. 2006) 
No change (Lee, H. Y. et al. 2006; Lee, H. Y. et al. 2005; Fan, S. L. et al. 
2008; Rippe, B. et al. 2001)
1 No clinical trials have been published whose primary objective is the study of these items 
Table 4. Beneficial effects of new glucose solutions in clinical practice 
3.1 GDPs 
GDPs are the main contributors to the bioincompatibility of PD solutions. Heat sterilization 
of the solutions facilitates the formation of GDPs, especially if the pH of the glucose 
chamber is high. GDPs are small molecules generated from glucose (Table 5 and Fig. 2). 
Many GDPs are toxic and more reactive than glucose with proteins to form AGEs such as 
pentosidine, N (epsilon) - (carboxymethyl) lysine (CML) and others. AGEs cause protein 
dysfunction and activate a specific receptor (RAGE, receptor for AGE) which transmits 
intracellular signals that modify cell behavior. Several GDPs are toxic, but only 3,4-
dideoxyglucoson-3-ene (3,4-DGE) has been shown to be lethal for leukocytes and 
mesothelial cells at the concentrations usually found in commercial PD bags (Justo, P. et al. 
2005; Santamaria, B. et al. 2008; Catalan, M. P. et al. 2005). 3-deoxyglucosone (3-DG), the 
precursor of the 3,4-DGE, is also cytotoxic, although high concentrations (around 500 µM) 
are needed to observe cytotoxicity. These high concentrations have not been found by most 
authors in the PD solutions tested (Table 5). 
The concentration of GDPs depends mainly on the pH of sterilization of glucose, on glucose 
concentration (higher GDP generation in solutions containing 4.25% glucose than in 1.5% 
glucose solutions) and on storage temperature (Erixon, M. et al. 2006; Erixon, M. et al. 2005; 
Erixon, M. et al. 2004). The lower the pH of sterilization of glucose, the lower the generation 
of GDPs. The optimal pH of sterilization to decrease the production of GDPs is  
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GDP Conventional 
glucose1 
Biocompatible
 glucose1,2 
Icodextrin  Aminoacids 
3-deoxiglucosone 172-425 10 4-11 <0.2 
3,4-DGE3 10-125 0.2-0.5 3 <0.2 
5-HMF  6-15 10 to 19 2 - 
Methylglyoxal 2-12 <1 1.5 <0.2 
Glyoxal <3-14 <1 2.5 <0.2 
Acetaldehyde 120-420 <2 37 - 
Formaldehyde 7-13 <3 9 - 
1 The range represents the values for glucose solutions with concentrations around 1.5 to 4% and 
measurements made by different authors. 
2 Excludes Physioneal that has higher values. 
3 The wide range observed depends on the concentration of glucose as the time since the sterilization 
and storage conditions 
Ref: (Erixon, M. et al. 2006) 
Table 5. GDP content in µmol / L of different solutions PD 
 
 
 
Fig. 2. GDP generation from glucose in PD fluids during heat sterilization and storage. 
Successive dehydration steps of the glucose molecule lead to initial GDPs and these are 
subsequently degraded into smaller molecules. There is a temperature-dependent balance 
between 3-DG, 3-DA and 3,4-DGE. Increasing temperature shifts the equilibrium to the 
right, towards the most toxic compound, 3,4-DGE. High concentrations of glucose are 
cytotoxic and lead to AGE formation, but 3-DG and, above all, 3,4-DGE lead to higher 
cytotoxicity and AGE generation. The thick dashed lines represent the ability to induce 
biological effects. 3-DG: 3-deoxyglucosone, 3-DA: 3-deoxyaldos-2-ene, 3,4-DGE: 3,4-
dideoxyglucosone-3-ene, AGE: advanced glycation products. HMF: hydroxymethylfurfural. 
Adapted from reference (Ortiz, A. et al. 2006). Additional GDPs include furaldehyde, 
formaldehyde, acetaldehyde, methylglyoxal, glyoxal.  
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2.0 to 3.1 (Erixon, M. et al. 2006). It is not possible to achieve a pH so low in unicameral bags, 
since solutions at such low pH cannot be safely infused into the peritoneum. Therefore, 
conventional glucose-containing unicameral bags have a pH of approximately 5.5 and a 
high concentration of GDPs. The problem was solved using bi-or tricameral bags, which 
allow sterilization of the glucose solution in a low pH chamber, separated from the buffer 
which is contained in a compartment at high pH (Fig. 1). This system allows both to lower 
the production of GDPs and, by mixing the contents of both chambers before the infusion, to 
infuse a solution at more physiological pH (6.3 to 7.4). 
The concentration of the most toxic GDP identified so far, 3,4-DGE, varies with storage 
temperature conditions: it is higher immediately post-heat sterilization, reaches a nadir at 2 
months of storage at room temperature (25 ° C), but may rise again if the bag is exposed for 
hours at higher temperatures (Erixon, M. et al. 2005). These higher temperatures may be 
reached during the summer at patient’s homes or during transportation. This has rekindled 
interest in transport and storage temperature of the solutions, especially in the summer 
months. This problem with sterilization and storage temperatures is not observed with the 
newer bicameral or tricameral having a pH <3.0 in the glucose chamber. 
4. Conventional PD solutions 
Conventional solutions are those contained in unicameral bags, with glucose as an osmotic 
agent and lactate as buffer. These solutions have a low pH and high GDP content and 
present the biocompatibility problems mentioned in previous sections, in addition to the 
continuous glucose absorption from the peritoneum and the high concentration of 
intraperitoneal glucose. 
4.1 Glucose as osmotic agent 
Glucose is the only osmotic agent which has proved safe and effective for chronic use in 
multiple exchanges within a 24 hour period. It is cheap and provides calories. However, it is 
not the ideal osmotic agent and poses several problems. Thus, the high concentrations of 
glucose required to induce ultrafiltration may facilitate or exacerbate: 
 Hyperglycemia with hyperinsulinemia, as well as undetected peaks of hyperglycemia 
in diabetics 
 Hyperlipidemia 
 Obesity 
 Conventional solutions damage the long-term peritoneal membrane, although in most 
studies it is not possible to tell apart the effect of glucose from the effect of GDPs 
(Davies, S. J. et al. 2001). 
In addition, glucose-containing PD solutions are not effective in promoting ultrafiltration in 
patients with high peritoneal transport. This is so because the high transporters absorb 
glucose from the peritoneum at a faster rate, thus dissipating the osmotic gradient that 
favours ultrafiltration earlier. Glucose uptake varies with the type of peritoneal transport of 
small solutes, which is a patient-specific feature (high transporters absorb more), with the 
dwell time (higher amounts of glucose are absorbed in more prolonged exchanges) and the 
concentration of glucose in the bag. It has been estimated that the average patient on CAPD 
absorbs from the peritoneum between 100-200 g glucose/24 h (about 8 kcal / kg / d) 
(Dombros, N. et al. 2005). 
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4.2 pH 
Conventional dextrose solutions have a pH of 5.5 (range 5-6). The low pH prevents 
caramelization of glucose during heat sterilization and reduces, but does not prevent the 
generation of GDPs. A lower pH may decrease GDP generation, but causes pain during 
infusion and possibly other adverse effects in the longer term. In fact, the pH of 5.5 causes 
pain in some patients. This pH is rapidly buffered by bicarbonate which diffuses from the 
circulation into the peritoneal cavity, reaching on average 7.0 in 30 minutes and above 7.30 
in 90-120 minutes (Schmitt, C. P. et al. 2002). The new PD solutions with higher pH are 
painless during infusion and the pH is already physiological during infusion or is 
normalized faster. 
5. New PD solutions 
We distinguish two approaches to the design of new PD solutions (Table 3) (McIntyre, C. 
W.2007; Montenegro, J. et al. 1993). One is to use of bi- or tricameral bags to improve glucose 
solutions, so that GDP content decreases and final pH approaches physiological values, with 
or without a total or partial change of the buffer. The other is to replace glucose by other 
osmotic agents such as icodextrin or amino acids, keeping lactate as buffer. 
The aim of this greater biocompatibility is to achieve better clinical results. The advantages 
of the newer, more biocompatible have been well documented in cell culture and animal 
studies. However, the big differences observed in basic research are more difficult to 
convincingly demonstrate in humans and some studies have failed to show such 
superiority.  
5.1 Biocompatible glucose solutions presented in bi- or tricameral bags 
Bi or tricameral bags allow to sterilize glucose at low pH and separate the bicarbonate 
(when present) from calcium and magnesium (Fig. 1). The differential characteristics of 
biocompatible glucose-containing solutions contained in bi or tricameral bags versus 
conventional, bioincompatible solutions are basically three: the low GDP concentration, a 
more physiological final pH, often around 7-7.4; and, in some cases, a pure bicarbonate or 
bicarbonate plus lactate buffer.  
However, not all biocompatible glucose solutions presented in bi- or tricameral bags 
areequal and their impact on clinical parameters should be assessed individually. Thus, 
there are differences in glucose concentration, buffer (bicarbonate, bicarbonate/lactate or 
lactate), pH of the glucose chamber and, thus, in GDP content, and in the final pH of 
infusion of the solutions, once the contents of all the chambers has been mixed pre-infusion 
is more physiological (6.3-7.4). 
Advantages and indications. The main advantage of these solutions is greater 
biocompatibility resulting from the low concentration of GDPs, physiological pH and, in 
some cases, absence of lactate. More biocompatibility suggests that these solutions should be 
the choice if there are resources to pay for them. Their use has resulted in improvement in 
surrogate parameters in clinical trials and observational studies including a higher 
peritoneal effluent concentration of CA125 (considered by many as a marker of mesothelial 
mass), lower rate of apoptosis in the effluent, lower concentration of circulating AGEs, 
better control of metabolic acidosis, better preservation of residual renal function, lower 
incidence of peritonitis, and in Registry studies, lower mortality (Table 4) (Montenegro, J. et 
al. 2007; Montenegro, J. et al. 2006; Williams, J. D. et al. 2004; Kim, S. G. et al. 2008; Lee, H. Y. 
www.intechopen.com
 
Progress in Peritoneal Dialysis 
 
174 
et al. 2005; Navarro, J. F. et al. 1999; Rippe, B. et al. 2001; Fan, S. L. et al. 2008; Ahmad, S. et 
al. 2006; Carrasco, A. M. et al. 2001; Fusshoeller, A. et al. 2004; Jones, S. et al. 2001; Haas, S. et 
al. 2003). As indicated above, the different characteristics of the various commercially 
available biocompatible solutions do not allow concluding that the observed effects are class 
effects. However, there are no direct clinical comparisons between the different solutions (from 
different providers) on the market and currently available information is incomplete, since not 
all possible effects have been studied with all the solutions. The effect on residual renal 
function has been the focus of three long-term randomized studies (12-18 months) with three 
solutions of different characteristics (Kim, S. G. et al. 2008; Fan, S. L. et al. 2008). Solutions with 
lower content GDPs better preserved residual renal function (Kim, S. G. et al. 2008). 
Several experimental reports support the bioincompatibility of conventional PD solutions 
(heat-sterilized glucose-containing solutions). Prolonged exposure to conventional PD 
solutions exert deleterious effects on the peritoneum, including loss of mesothelial cell 
monolayer, submesothelial fibrosis, angiogenesis, hyalinizing vasculopathy and impaired 
viability and function of human peritoneal mesothelial cells (HPMC) and leukocytes (Jorres 
A KI 2008 (Yanez-Mo, M. et al. 2003; Vargha, R. et al. 2006; Santamaria, B. et al. 2008; 
Williams, J. D. et al. 2002). The adverse effects may lead, in the long-term to ultrafiltration 
failure and PD technique withdrawal. GDPs have been identified as the major cytotoxic 
agents in conventional PD solutions. GDPs impair viability, cell function, cytokine release 
on HPMC, induce apoptosis and promote EMT in mesothelial cells and impair leukocyte 
function and viability (Amore, A. et al. 2003; Witowski, J. et al. 2000; Witowski, J. et al. 2001; 
Witowski, J. et al. 2001; Morgan, L. W. et al. 2003) (Oh, E. J. et al. 2010). In addition, the 
number of mesothelial cell dying by apoptosis is increased in the effluent of patients using 
high GDP PD solutions vs. patients using low GDP PD solutions (Santamaria, B. et al. 2008). 
3,4 deoxyglucosone-3 ene (3,4 DGE) is the main cytotoxic product in conventional PD 
solutions. 3,4 DGE accelerates leukocyte and HPMC apoptosis, to the same extent as 
conventional PD solution, retards remesothelization and may compromise peritoneal 
defense (Santamaria, B. et al. 2008; Catalan, M. P. et al. 2005; Morgan, L. W. et al. 2003; 
Linden, T. et al. 2002; Yamamoto, T. et al. 2009). The poor biocompatibility of PD solutions 
may also compromise peritoneal defenses and promote peritonitis or a poor resolution of 
peritonitis episodes. At the molecular at cellular level peritonitis is characterized by cytokine 
release and leukocyte recruitment to the peritoneal cavity (Zemel, D. et al. 1996; Li, F. K. et 
al. 1998). However neutrophils die spontaneously by apoptosis at sites of inflammation and 
accelerated leukocyte apoptosis may impair the peritoneal defense. Indeed bioincompatible 
PD solutions accelerate neutrophil apoptosis and this has been shown retard recovery from 
S aureus peritonitis in mice exposed to PD solutions (Catalan, M. P. et al. 2003). Neutrophil 
apoptosis is a physiologic process that limits inflammation. However, premature neutrophil 
apoptosis may compromise the antibacterial potential of these leukocytes. Conventional PD 
solutions accelerated leukocyte apoptosis in vivo and in vitro (Catalan, M. P. et al. 2003; 
Catalan, M. P. et al. 2005). In vitro studies, also show that 3,4 DGE accelerated neutrophils 
and mononuclear cell apoptosis and increased HPMC death in the same way as 
conventional PD solutions, but biocompatible PD solutions (low content GDPs, double 
chambered PD solutions) maintains low apoptosis levels as controls (Santamaria, B. et al. 
2008)`79]. Mesothelial cells also die by apoptosis during peritonitis due to the combination 
of high levels of lethal cytokines and bioincompatible PD solutions as demonstrated in an 
experimental mice model of S. aureus peritonitis and following the intraperitoneal 
administration of inflammatory cytokines (Santamaria, B. et al. 2009)  
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Regarding the clinical evidence on the biocompatibility of glucose-based PD solutions (table 
1), there is information from non-randomized observations and from clinical trials.  
A retrospective observational study compared outcomes for 1100 incident CAPD patients 
treated with a single chamber peritoneal dialysis fluid (PDF) to the outcomes for patients 
treated with a low GDP double chamber PDF. Patients treated with Balance had 
significantly superior survival compared to those treated with the standard PDF (74% vs 
62% at 28 months, p = 0.0032). This study was not stratified by age, the high number of 
patients with standard PDF and the absence of parameters like RRF, dialysis adequacy, 
transport status that are more related with survival (Lee, H. Y. et al. 2005).  
A prospective non-randomized study of incident patients compared a conventional lactate 
solution (lactate group) to a pure bicarbonate solution (bicarbonate group) PD solution in 
100 patients followed for three years in both groups (Montenegro, J. et al. 2007). The 
peritonitis rate was lower in patients treated with the pure bicarbonate solution than 
patients treated with the standard bioincompatible solution: 1 episode for each 36 patient-
months versus 1 episode every 21 patient-months. At the end of the study, the RRF was 
significantly better preserved in patients of the bicarbonate group. Patients treated with 
pure bicarbonate ate more proteins according to normalized protein catabolic rate 
calculations and had lower markers of inflammation such as C reactive protein. Even 
mortality was lower in the bicarbonate group, even though this group had a higher 
Charlson index. 
Several randomized controlled trials have focused mainly on preservation of RRF.  
A crossover study compared the impact of a 25 mmol/L bicarbonate/15 mmol/L lactate 
buffered, solution (Physioneal) with a standard single chamber solution (Dianeal) (Fang, W. et 
al. 2008) on peritoneal transport and ultrafiltration. The mass transfer area coefficients (urea 
and creatinine) for both solutions did not differ. However net ultrafiltration was lower for 
Bic/Lac solution (274 ± 223 mL vs 366 ± 217 mL, p = 0.026). Physioneal avoided intraperitoneal 
acidity, which is present for up to 120 minutes with conventional acidic lactate solution. 
The Euro-Balance trial with a crossover design and parallel arms, compared a single 
chamber conventional glucose-containing fluid with a lactate-buffered, low GDP double 
chamber glucose-containing fluid (balance) (Williams, J. D. et al. 2004). Clinical end points 
were RRF, adequacy of dialysis, ultrafiltration and peritoneal membrane function. Balance 
resulted in significantly higher effluent levels of CA125 and procollagen peptide in both 
arms of the study. Conversely, levels of Hialuronic acid were lower in patients exposed to 
balance, while there was no change in the levels of either VEGF or TNFa. Urine volume was 
higher in patients exposed to balance. In contrast, peritoneal ultrafiltration was higher in 
patients on conventional fluids. Increased extracellular volume and lower ultrafiltration in 
the patients with biocompatible solutions may be conditioning the results. The follow-up 
was short and changes in the RRF were a secondary objective. 
A trial of incident patients starting PD examined changes in RRF (assessed by 24-h urine 
collection) over a1-year follow-up (Fan, S. L. et al. 2008). No differences were found between 
groups, for RRF, peritonitis rate, PD technique survival, changes in peritoneal membrane 
function assessed by peritoneal equilibrium test or C-reactive protein. Issues criticized in this 
study include the lack of statistical power to establish non inferiority as the difference of less 
than 1 ml / min in the RRF, use of solutions with different GDP content, inclusion of previous 
hemodialysis patients with little RRF and assessment of RRF at only two time points. 
In 2009 three trials were published showing the benefit of biocompatible solutions in regard 
to RRF, ultrafiltration and tolerability. 
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A study of 91 incident CAPD patients for 12 months compared neutral-pH and low GDP 
(Balance) and conventional solutions (Kim, S. et al. 2009). Biocompatible solution preserved 
RRF compared with conventional solutions (p=0.048). Analysis by subgroups (GFR>2 
ml/min) demonstrated the preservation of RRF in per protocol analysis. 
In a crossover study with 26 prevalent patients treated for 3 months with lactate-based and 3 
months with bicarbonate/lactate-based solution (Pajek, J. et al. 2009), switch from 
conventional solutions to biocompatible solution decreased ultrafiltration (p=0.012) and switch 
from biocompatible to conventional solution increased ultrafiltration solutions (p=0.001). 
A cross over multicenter trial (Weiss, L. et al. 2009) enrolled 53 patients and compared 
conventional vs Bicarbonate PD fluid. Patients with biocompatible solutions had a higher 
concentration of CA125 (p<0.001) and less concentration of hyaluronic acid (p=0.013), TNF-
┙ (p<0.001) and TGF-┚1 (p=0.016). These biocompatibility markers suggest improvement in 
peritoneal membrane integrity In addition, a positive effect on RRF was observed (p=0.011). 
Drawbacks. Biocompatible, glucose-containing PD solutions maintain the adverse effects of 
glucose itself. 
In addition, a surprising effect of ultrafiltration has been observed that was not anticipated 
by experimental studies in animals. Biocompatible, glucose-containing PD solutions 
buffered with lactate or bicarbonate decrease ultrafiltration compared to conventional 
solutions in some patients: In some cases this is related to increased peritoneal transport of 
small molecules (Williams, J. D. et al. 2004). This effect is acute (observable with a single 
exchange) and reversible by discontinuing the solution. Furthermore, the decreased 
ultrafiltration observed with biocompatible glucose-containing PD solutions is not 
indicative of peritoneal injury and in this, it differs from the progressive increase in solute 
permeability observed over the years in PD as a result of peritoneal injury induced by 
conventional solutions. The results obtained when assessing the impact of 
lactate/bicarbonate-buffered PD solutions have not been consistent. However, a recent 
study showed a decrease in ultrafiltration compared to conventional solutions when 
compared in the same patient in a short period of time (Fang, W. et al. 2008). The interest in 
learning about differences in the behavior of the various solutions lies in a better 
understanding of the cause of these differences, which could be related to differences in pH, 
buffer or GDP content. A recently reported very low GDPs solution, with physiological pH 
and buffered with bicarbonate / lactate increased ultrafitración against a similar solution 
containing GDPs, pH 6.3 and lactate (Simonsen, O. et al. 2006). 
An additional caveat should be made. In some patients bicarbonate-buffered solutions can 
overcorrect the metabolic acidosis of uremia, causing metabolic alkalosis (Vande Walle, J. G. 
et al. 2004; Garcia-Lopez, E. et al. 2005; Otte, K. et al. 2003). 
5.2 Alternative osmotic agents 
Icodextrin and amino acids are the only alternative to glucose agents that are commercially 
available. 
5.2.1 Icodextrin 
Polyglucose or icodextrin is a carbohydrate of high molecular weight obtained by hydrolysis 
of corn starch (Figure 3) (Frampton, J. E. et al. 2003). Icodextrin consists of a mixture of 
glucose polymers of different sizes (from 2 to 300 molecules of glucose) with a total average 
molecular weight of 13 to 19 KDa and average molecular weight per molecule of 5 to 6.5 
KDa (range 0.36-54). Icodextrin is available commercially at a concentration of 7.5%. 
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However, icodextrin cannot be strictly considered a biocompatible solution, due to the 
intrinsic problems of the glucose polymer, such as generation high levels of circulating 
maltose in the systemic circulation. In this regard, no more than one exchange a day can be 
prescribed according to heath authorities. 
 
 
Fig. 3. Schematic representation of molecules of glucose, maltose, icodextrin polymers and 
intermediates. 
Advantages and indications. Icodextrin-containing solutions are isosmolar and induce 
ultrafiltration by oncotic pressure. Icodextrin is absorbed by lymphatic vessels, more slowly 
than glucose. As a consequence, the oncotic pressure is durable and ultrafiltration is linear 
and more sustained than that induced by glucose. During an exchange of 10-16 hours 40% of 
icodextrin in an exchange is absorbed (Garcia-Lopez, E. et al. 2005; Moberly, J. B. et al. 2002). 
These features suggest the following icodextrin indications: 
a. Long daytime exchange in APD (as the last cycler infusion) or the night dwell during 
CAPD in order to increase ultrafiltration and sodium removal (Davies, S. J. et al. 2005; 
Rodriguez-Carmona, A. et al. 2002; Davies, S. J. et al. 2008). In randomized controlled 
trials icodextrin improved the hydration status of patients ((Davies, S. J. et al. 2008; 
Wolfson, M. et al. 2002; Plum, J. et al. 2002). Icodextrin allows greater ultrafiltration in long 
exchanges than solutions with 1.5% or 2.3% glucose. Furthermore, icodextrin allows 
greater ultrafiltration in long exchanges than 4.25% glucose in high transporters. Since 
icodextrin is not a small molecule, ultrafiltration may be obtained with icodextrin in 
patients with failure of ultrafiltration due to high transport of small solutes. The ability to 
obtain ultrafiltration in these patients can prolong the life of the PD technique, delaying 
the transition to hemodialysis. More ultrafiltration allows a greater clearance of molecules 
when comparing a prolonged exchange (approx. 12 hours) of icodextrin with a glucose 
exchange of the same duration, especially if the concentration of glucose is 1.5% (Wolfson, 
M. et al. 2002). However, solute clearance is less with a long exchange of icodextrin than 
with two shorter glucose exchanges (approx 6 hours per glucose exchange). 
b. Limit exposure to high concentrations of glucose and GDPs and absorption of glucose. 
This can help to preserve the functionality of the peritoneal membrane (Davies, S. J. et al. 
2005). Although there are few differences in the absorption of the total amount of 
carbohydrates, icodextrin prevents the absorption peaks of glucose. This may contribute 
to less weight gain, lipid abnormalities and improved glycemic control and HbA1c levels 
in poorly controlled diabetic patients (Wolfson, M. et al. 2002; Babazono, T. et al. 2007). 
c. Maintenance of ultrafiltration during episodes of peritonitis since the ultrafiltration 
capacity of icodextrin solutions is independent of peritoneal permeability to small solutes. 
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Peculiarities. Amylase degrades icodextrin, but in humans there is little amylase in the 
peritoneal cavity (unlike in some rodents). Absorbed icodextrin is degraded by circulating 
amylase. The consequences of icodextrin degradation by circulating amylase may be 
summarized as follows: 
a. Increased plasma concentration of maltose (maltose 20-300 times increased over 
physiological levels to 120 mg/dl or 3 mM, compared to physiological glucose 
concentrations from 3.3 to 5.5 mM), maltotriose and other glucose polymers (Garcia-
Lopez, E. et al. 2005; Burkart, J.2004; Posthuma, N. et al. 1997). These metabolites are 
normally excreted in the urine or degraded to glucose by tissue maltase tissue. The 
richest tissue in maltase is the kidney. In renal failure these two mechanisms of 
elimination fail, facilitating maltose accumulation. This risk of maltose accumulation 
limits the use of icodextrin to a single exchange within a 24 hour period. So far, no toxic 
effects have been identified resulting from accumulation of maltose when icodextrin is 
used according to the prescription data sheet. 
b. Maltose and other oligosaccharides that accumulate in the blood of patients treated 
with icodextrin interfere with some plasma glucose monitors and test strips readings, 
resulting in falsely elevated glucose readings (Wang, R. et al. 2004; Wens, R. et al. 1998). 
In patients treated with icodextrin only glucose monitors and test strips that use 
glucose-specific methods should be used. These include methods based on glucose 
oxidase (GO), hexokinase, glucose dehydrogenase nicotine adenine dinucleotide (GDH-
NAD), or glucose dehydrogenase with flavin adenine dinucleotide (GDH-FAD). 
Methods not to be used include glucose dehydrogenase pirrolquinolinaquinone (GDH-
PQQ) or glucose-dye-oxidoreductase, which detect both glucose and maltose. After 
stopping the use of icodextrin it takes around 14 days for the plasma levels of icodextrin 
and its metabolites to return to undetectable (Plum, J. et al. 2002). 
c. Mild decline in serum sodium without hypo-osmolarity to values around 135-137 mmol 
/ L. This is associated with an increased osmolal gap due to the presence of circulating 
metabolites of icodextrin (which justify an increase in osmolal gap of about 8 mOsm / 
kg) (Plum, J. et al. 2002; Posthuma, N. et al. 1997). 
d. Decrease in measured plasma amylase levels, because the circulating metabolites of 
icodextrin interfere with the assay (Plum, J. et al. 2002). So if pancreatitis is suspected, 
lipase should be assayed. 
Adverse effects. The most common side effect of icodextrin in clinical trials was skin 
hypersensitivity (2.5-5% of exposed individuals), which usually occurs in the first 3 weeks 
and require discontinuation of treatment, although in some patients the rash disappears 
despite continued use of icodextrin (Frampton, J. E. et al. 2003; Wolfson, M. et al. 2002). 
In the late 90s and early 2000s there was an epidemic of sterile peritonitis in patients treated 
with icodextrin. The cause was contamination of some lots with peptidoglycan, a component 
of the wall of gram-positive bacteria (Goffin, E. et al. 2003). New control systems of production 
have largely eliminated the problem and no influence has been observed of icodextrin on 
peritonitis incidence rates, either culture positive or negative (Vychytil, A. et al. 2008). 
5.2.2 Amino acids 
PD solutions containing amino acid solutions can limit the use of glucose. In addition, 
amino acids provide nutritional components (Tjiong, H. L. et al. 2005). The only marketed 
solution contains 1.1% amino acids, equivalent to an amino acid concentration of 87 mM / L 
(Table 6). The average molecular weight of the amino acids is 126. Approximately 65% of 
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them (15 g/exchange) are absorbed into the systemic circulation during a 4-6h PD exchange. 
This is enough to replace the approximately 5-8 g/day of protein and 3 g/day of amino 
acids that are lost in non-aminoacid PD exchanges (Rippe, B. et al. 2007). The osmotic power 
of the amino acid solutions is comparable to a solution of 1.5% glucose. The osmolarity is 
slightly higher than the 1.5% glucose solution and a slightly higher ultrafiltration has been 
reported, approximately 100 ml at 4 h, despite a greater absorption of the osmotic agent. The 
increased uptake is probably due to the lower average molecular weight of the amino acids 
and to amino acid-induced vasodilation (Rippe, B. et al. 2007; Olszowska, A. et al. 2007). 
 
Aminoacid Concentration 
(mM/L) 
L-Valine  11.88 
L-Alanine  10.67 
L-Leucine  7.79 
Glycine  6.80 
L-Lysine, HCl  6.51 
L-Isoleucine  6.49 
L-Arginine  6.15 
L-Methionine  5.70 
L-Threonine 5.46 
L-Proline  5.13 
L-Serine  4.86 
L-Histidine  4.58 
L-Phenylalanine 3.45 
L-Tyrosine 1.66 
L-Tryptophan 1.32 
Table 6. Aminoacid concentration in the only commercially available aminoacid PD solution 
Advantages and indications. The use of amino acids as osmotic agents decreases peritoneal 
glucose load and glucose uptake from the peritoneal cavity. This is especially relevant in 
diabetic and obese individuals. Amino acid solutions also are moderately effective as a 
nutritional supplement in malnourished patients. In short-term studies protein synthesis 
improved when amino acid solutions were associated with an adequate supply of calories, 
such as oral intake or by combining aminoacids with glucose in cycler (Garibotto, G. et al. 
2001; Tjiong, H. L. et al. 2005; Tjiong, H. L. et al. 2007). The effect tends to be less consistent 
in the long-term, probably because other factors influence serum albumin such as 
inflammation, acidosis or inadequate calorie intake (Kopple, J. D. et al. 1995). However, in a 
3-year study malnourished patients using 1.1% amino acids better maintained serum 
albumin (Li, F. K. et al. 2003). A decrease of serum phosphorus has also been reported and 
attributed to the contribution of amino acids in the absence of phosphate (Kopple, J. D. et al. 
1995). In this sense, the same amount of amino acid if ingested orally, is associated with 
approximately 300 mg of phosphate. 
Drawbacks. Amino acid solutions can only be used once daily since a higher number of 
bags favors acidosis (which can be compensated by oral treatment with bases or PD 
solutions with higher buffer content) and increases urea (Tjiong, H. L. et al. 2007; Kopple, J. 
D. et al. 1995; le Poole, C. Y. et al. 2005). The tendency to acidosis and uremia is more 
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pronounced in catabolic patients, so factors that promote catabolism should be corrected 
and an adequate calorie intake should be maintained to prevent the catabolism of amino 
acids as an energy source. This can be achieved with oral caloric intake or by mixing amino 
acid containing PD solutions with glucose solutions simultaneously in the cycler exchanges. 
In addition, the methionine load from the dialysate may significantly increase plasma 
homocysteine levels, especially in patients with lower protein and methionine intakes 
(Yang, S. Y. et al. 2005). Increased plasma homocysteine levels have been associated with 
impaired cardiovascular outcomes. In this regard, one 6-h dwell with a commercial amino 
acid dialysis solution acutely impaired forearm reactive hyperemia, a marker of endothelial 
dysfunction, in smoking and nonsmoking PD patients (Vychytil, A. et al. 2003).  
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